Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7007243 | 0.73 | RAB9A (0.50) | RAB9ASMN1; SMN2MAPTNPC1TDP1 | |
| SCHEMBL5458568 | 0.72 | TAAR1 (0.46) | RAB9ASMN1; SMN2NPC1NTRK1NTRK3 | |
| SCHEMBL5758133 | 0.72 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL5760121 | 0.72 | HTT (0.44) | RAB9ANPC1L3MBTL1POLB | |
| SCHEMBL5759825 | 0.71 | TRPM8 (0.39) | RAB9ASMN1; SMN2MAPTNPC1L3MBTL1 | |
| SCHEMBL5759976 | 0.70 | CHRM2 (0.40) | MAPTTDP1L3MBTL1NTRK1CYP1B1 | |
| SCHEMBL5757035 | 0.70 | ACACB (0.30) | — | |
| SCHEMBL9899792 | 0.69 | — | — | |
| SCHEMBL5757399 | 0.69 | — | — | |
| SCHEMBL30753609 | 0.69 | KLK1 (0.33) | RAB9AKLK1KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1104403-B1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PROD INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050215549-A1 | TACE inhibitors | MCCLURE KIM F | 2005-09-29 | — | — | US | disclosed |
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | disclosed |
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MCCLURE KIM F (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| US-6329397-B1 | TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. | PFIZER | 2001-12-11 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1104412-A1 | TACE INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1104403-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009485-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009492-A1 | TACE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | ADAMTS5, ADAMTS1, MMP2 | RAB9A 399/4885SMN1; SMN2 3890/4885MAPT 2382/4885 |
| US-20050215549-A1 | TACE inhibitors | ADAMTS5, ADAMTS1, MMP2 | RAB9A 502/4885SMN1; SMN2 3804/4885MAPT 1916/4885 |
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | RAB9A 1591/4885SMN1; SMN2 2083/4885MAPT 2469/4885 |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MMP1, MMP10, MMP3 | RAB9A 1158/4885SMN1; SMN2 3318/4885MAPT 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.